Home1TWST • BIT
add
Twist Bioscience Corp
Previous close
€28.61
Year range
€19.50 - €34.57
Market cap
1.99B USD
Avg Volume
80.00
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Revenue | 96.06M | 17.91% |
Operating expense | 81.42M | 2.72% |
Net income | 20.39M | 123.83% |
Net profit margin | 21.23 | 120.21% |
Earnings per share | -0.47 | 33.22% |
EBITDA | -24.06M | 32.60% |
Effective tax rate | 0.93% | — |
Balance Sheet
Total assets
Total liabilities
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Cash and short-term investments | 250.80M | -13.34% |
Total assets | 643.60M | 0.86% |
Total liabilities | 165.41M | 12.54% |
Total equity | 478.20M | — |
Shares outstanding | 60.36M | — |
Price to book | 3.60 | — |
Return on assets | -12.15% | — |
Return on capital | -13.61% | — |
Cash Flow
Net change in cash
| (USD) | Jun 2025info | Y/Y change |
|---|---|---|
Net income | 20.39M | 123.83% |
Cash from operations | -1.40M | 78.05% |
Cash from investing | -9.40M | -1,221.66% |
Cash from financing | 1.83M | -37.21% |
Net change in cash | -9.04M | -116.37% |
Free cash flow | -1.74M | -128.89% |
About
Twist Bioscience is a public biotechnology company based in South San Francisco that manufactures synthetic DNA and DNA products for customers in a wide range of industries. Twist was founded in 2013 by Emily Leproust, Bill Banyai, and Bill Peck.
The company was represented by Leproust at a March 2021 tabletop exercise at the Munich Security Conference simulating an outbreak of weaponized monkeypox.
In May 2021, Twist Bioscience and Genome Project-Write launched a new CAD platform for whole genome design. The CAD will automate workflows to enable collaborative efforts critical for scale-up from designing plasmids to megabases across entire genomes. Wikipedia
Founded
2013
Website
Employees
923
